Stephen K. Brannan - 11 Jul 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
11 Jul 2022
Net transactions value
-$1,861,350
Form type
4
Filing time
11 Jul 2022, 18:30:18 UTC
Previous filing
09 Jun 2022
Next filing
11 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $138,000 +15,000 +100% $9.20* 30,000 11 Jul 2022 Direct
transaction KRTX Common Stock Sale $1,999,350 -15,000 -50% $133.29 15,000 11 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -15,000 -30% $0.000000 34,989 11 Jul 2022 Common Stock 15,000 $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.28 to $133.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.